留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

整合素RGD受体显像临床应用专家共识(2022版)

中华医学会核医学分会,中国生物物理学会分子影像学分会

中华医学会核医学分会,中国生物物理学会分子影像学分会. 整合素RGD受体显像临床应用专家共识(2022版)[J]. 协和医学杂志, 2022, 13(2): 227-234. doi: 10.12290/xhyxzz.2022-0089
引用本文: 中华医学会核医学分会,中国生物物理学会分子影像学分会. 整合素RGD受体显像临床应用专家共识(2022版)[J]. 协和医学杂志, 2022, 13(2): 227-234. doi: 10.12290/xhyxzz.2022-0089
Chinese Society of Nuclear Medicine, Chinese Society of Molecular Imaging in Chinese Biophysical Society. Expert Consensus on Clinical Application of Integrin RGD Receptor Imaging (2022)[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(2): 227-234. doi: 10.12290/xhyxzz.2022-0089
Citation: Chinese Society of Nuclear Medicine, Chinese Society of Molecular Imaging in Chinese Biophysical Society. Expert Consensus on Clinical Application of Integrin RGD Receptor Imaging (2022)[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(2): 227-234. doi: 10.12290/xhyxzz.2022-0089

整合素RGD受体显像临床应用专家共识(2022版)

doi: 10.12290/xhyxzz.2022-0089
基金项目: 

国家自然科学基金 81871392

中国医学科学院医学与健康科技创新工程 2021-I2M-1-016

首都卫生发展科研专项 2018-1-4011

广州实验室应急攻关项目 EKPG21-16

中国医学科学院临床转化基金 2019XK320032

详细信息

    通讯作者:朱朝晖1,2,E-mail: zhuzhh@pumch.cn
    李思进3,E-mail: lisjnm123@163.com
    王凡4,E-mail: wangfan@bjmu.edu.cn
    1. 中国医学科学院北京协和医院核医学科 核医学分子靶向诊疗北京市重点实验室,北京 100730
    2. 中国医学科学院北京协和医院疑难重症及罕见病国家重点实验室,北京 100730
    3. 山西医科大学第一医院核医学科,太原 030001
    4. 北京大学医学同位素研究中心,北京 100191

  • 中图分类号: R445

Expert Consensus on Clinical Application of Integrin RGD Receptor Imaging (2022)

Funds: 

National Natural Science Foundation of China 81871392

CAMS Innovation Fund for Medical Sciences 2021-I2M-1-016

The Capital Health Development Scientific Research Project 2018-1-4011

Emergency Key Program of Guangzhou Laboratory EKPG21-16

CAMS Clinical and Translational Medicine Research Fund 2019XK320032

More Information

    Corresponding authors: ZHU Zhaohui1, 2, E-mail: zhuzhh@pumch.cn
    LI Sijin3, E-mail: lisjnm123@163.com
    WANG Fan4, E-mail: wangfan@bjmu.edu.cn
    1. Department of Nuclear Medicine, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China
    2. State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China
    3. Department of Nuclear Medicine, First Hospital of Shanxi Medical University, Taiyuan 030001, China
    4. Medical Isotopes Research Center, Peking University, Beijing 100191, China

  • 摘要: 整合素是一类跨膜糖蛋白,介导细胞与细胞、细胞与细胞外间质之间的黏附及信号传导,调节细胞的黏附、迁移、增殖和凋亡等功能,在新生血管内皮细胞及多种恶性肿瘤细胞表面高表达。基于精氨酸-甘氨酸-天冬氨酸(arginine-glycine-aspartate,RGD)结构的多肽能够与整合素αVβ3等亚型特异结合,通过单光子发射计算机断层成像或正电子发射断层成像,无创、在体显示肿瘤的浸润转移特性以及评估血管新生情况等,具有较大的临床应用价值。基于国际、国内相关临床研究最新进展,本专家共识旨在建立整合素RGD受体显像临床应用的指导原则。
    作者贡献:朱朝晖负责查阅文献和撰写初稿;李思进、王凡修改完善并审校定稿;其余成员参与修订。
    利益冲突:共识制订工作组所有参与人员均声明不存在利益冲突
    共识核心专家组成员 (按姓氏首字母排序):
    兰晓莉(华中科技大学附属协和医院核医学科),李林(四川大学华西医院核医学科),李思进(山西医科大学第一医院核医学科),刘建军(上海交通大学仁济医院核医学科),马庆杰(吉林大学中日联谊医院核医学科),宋少莉(复旦大学肿瘤医院核医学科),王凡(北京大学医学同位素研究中心),王雪梅(内蒙古医科大学附属医院核医学科),辛军(中国医科大学附属盛京医院核医学科),杨志(北京大学肿瘤医院核医学科),张祥松(中山医科大学附属第一医院核医学科),朱朝晖(中国医学科学院北京协和医院核医学科)
  • 图  1  整合素的4种受体亚族、对应的亚型及其亚单位构成RGD: 精氨酸-甘氨酸-天冬氨酸

    表  1  已进入临床研究的整合素RGD受体显像剂及其特征

    显像剂 靶向受体 显像方式 形态 结构 PEG链
    99mTc-3PRGD2[6] αVβ3 SPECT 环化 二聚体
    99mTc-Galacto-RGD2[7] αVβ3 SPECT 环化 二聚体
    99mTc-NC100692[8] αVβ3 SPECT 环化 单体
    18F-AlfatideⅡ[9] αVβ3 PET 环化 二聚体
    18F-Alfatide[10] αVβ3 PET 环化 二聚体
    68Ga-PRGD2[11] αVβ3 PET 环化 二聚体
    68Ga-RGD[12] αVβ3 PET 环化 单体
    18F-FPPRGD2[13] αVβ3 PET 环化 二聚体
    18F-RGD-K5[14] αVβ3 PET 环化 单体
    18F-Galacto-RGD[15] αVβ3 PET 环化 单体
    68Ga-DOTA-SFLAP3[16] αVβ6 PET 环化 单体
    68Ga-SFITGv6[16] αVβ6 PET 环化 单体
    68Ga-cycratide[17] αVβ6 PET 环化 单体
    68Ga-Trivehexin[18] αVβ6 PET 环化 三体
    68Ga-NODAGA-R01-MG[19] αVβ6 PET 结状 单体
    18F-FP-R01-MG-F2[19] αVβ6 PET 结状 单体
    18F-αVβ6-BP[20] αVβ6 PET 线性 单体
    18F-fluciclatide[21] αVβ5和αVβ3 PET 环化 单体
    68Ga-NOTA-TATE-RGD[22] αVβ3和SSTR2 PET 环化 异二聚体
    68Ga-NOTA-BBN-RGD[23] αVβ3和GRPR PET 环化 异二聚体
    PEG:聚乙二醇;SPECT:单光子发射计算机断层成像;PET:正电子发射断层显像;RGD: 同图 1
    下载: 导出CSV
  • [1] Ludwig BS, Kessler H, Kossatz S, et al. RGD-binding integrins revisited: how recently discovered functions and novel synthetic ligands (re-)shape an ever-evolving field[J]. Cancers (Basel), 2021, 13: 1711. doi:  10.3390/cancers13071711
    [2] Kossatz S, Beer AJ, Notni J. It's time to shift the paradigm: translation and clinical application of non-alphavbeta3 integrin targeting radiopharmaceuticals[J]. Cancers (Basel), 2021, 13: 5958. doi:  10.3390/cancers13235958
    [3] Steiger K, Quigley NG, Groll T, et al. There is a world beyond alphavbeta3-integrin: multimeric ligands for imaging of the integrin subtypes alphavbeta6, alphavbeta8, alphav-beta3, and alpha5beta1 by positron emission tomography[J]. EJNMMI Res, 2021, 11: 106. doi:  10.1186/s13550-021-00842-2
    [4] Ebenhan T, Kleynhans J, Zeevaart JR, et al. Non-oncological applications of RGD-based single-photon emission tomography and positron emission tomography agents[J]. Eur J Nucl Med Mol Imaging, 2021, 48: 1414-1433. doi:  10.1007/s00259-020-04975-9
    [5] Chen H, Niu G, Wu H, et al. Clinical application of radiolabeled RGD peptides for PET imaging of integrin alphavbeta3[J]. Theranostics, 2016, 6: 78-92. doi:  10.7150/thno.13242
    [6] Zhu Z, Miao W, Li Q, et al. 99mTc-3PRGD2 for integrin receptor imaging of lung cancer: a multicenter study[J]. J Nucl Med, 2012, 53: 716-722. doi:  10.2967/jnumed.111.098988
    [7] Fu J, Xie Y, Fu T, et al. [(99m)Tc]Tc-Galacto-RGD(2) integrin alpha(v)beta(3)-targeted imaging as a surrogate for molecular phenotyping in lung cancer: real-world data[J]. EJNMMI Res, 2021, 11: 59. doi:  10.1186/s13550-021-00801-x
    [8] Verjans J, Wolters S, Laufer W, et al. Early molecular imaging of interstitial changes in patients after myocardial infarction: Comparison with delayed contrast-enhanced magnetic resonance imaging[J]. J Nucl Cardiol, 2010, 17: 1065-1072. doi:  10.1007/s12350-010-9268-5
    [9] Mi B, Yu C, Pan D, et al. Pilot prospective evaluation of (18)F-Alfatide Ⅱ for detection of skeletal metastases[J]. Theranostics, 2015, 5: 1115-1121. doi:  10.7150/thno.12938
    [10] Dong Y, Wei Y, Chen G, et al. Relationship between clinicopathological characteristics and PET/CT uptake in esophageal squamous cell carcinoma: [(18)F]Alfatide versus[(18)F]FDG[J]. Mol Imaging Biol, 2019, 21: 175-182. doi:  10.1007/s11307-018-1216-9
    [11] Zheng K, Liang N, Zhang J, et al. 68Ga-NOTA-PRGD2 PET/CT for integrin imaging in patients with lung cancer[J]. J Nucl Med, 2015, 56: 1823-1827. doi:  10.2967/jnumed.115.160648
    [12] Kim YI, Phi JH, Paeng JC, et al. In vivo evaluation of angiogenic activity and its correlation with efficacy of indirect revascularization surgery in pediatric moyamoya disease[J]. J Nucl Med, 2014, 55: 1467-1472. doi:  10.2967/jnumed.114.142430
    [13] Iagaru A, Mosci C, Mittra E, et al. Glioblastoma multiforme recurrence: an exploratory study of (18)F-FPPRGD2 PET/CT[J]. Radiology, 2015, 277: 497-506. doi:  10.1148/radiol.2015141550
    [14] Chen SH, Wang HM, Lin CY, et al. RGD-K5 PET/CT in patients with advanced head and neck cancer treated with concurrent chemoradiotherapy: Results from a pilot study[J]. Eur J Nucl Med Mol Imaging, 2016, 43: 1621-1629. doi:  10.1007/s00259-016-3345-1
    [15] Beer AJ, Pelisek J, Heider P, et al. PET/CT imaging of integrin αVβ3 expression in human carotid atherosclerosis[J]. JACC Cardiovasc Imaging, 2014, 7: 178-187. doi:  10.1016/j.jcmg.2013.12.003
    [16] Roesch S, Lindner T, Sauter M, et al. Comparison of the RGD motif-containing αVβ6 integrin-binding peptides SFLAP3 and SFITGv6 for diagnostic application in HNSCC[J]. J Nucl Med, 2018, 59: 1679-1685. doi:  10.2967/jnumed.118.210013
    [17] Feng X, Wang Y, Lu D, et al. Clinical translation of a (68)Ga-labeled integrinalpha(v)beta(6)-targeting cyclic radiotracer for PET imaging of pancreatic cancer[J]. J Nucl Med, 2020, 61: 1461-1467. doi:  10.2967/jnumed.119.237347
    [18] Quigley NG, Steiger K, Hoberück S, et al. PET/CT imaging of head-and-neck and pancreatic cancer in humans by targeting the "Cancer Integrin" alphavbeta6 with Ga-68-Trivehexin[J]. Eur J Nucl Med Mol Imaging, 2021, 24: 1-12.
    [19] Kimura RH, Wang L, Shen B, et al. Evaluation of integrin alpha v beta(6) cystine knot PET tracers to detect cancer and idiopathic pulmonary fibrosis[J]. Nat Commun, 2019, 10: 4673. doi:  10.1038/s41467-019-11863-w
    [20] Hausner SH, Bold RJ, Cheuy LY, et al. Preclinical development and first-in-human imaging of the integrin alphavbeta6 with[18F]alphavbeta6-binding peptide in metastatic carcinoma[J]. Clin Cancer Res, 2019, 25, 1206-1215.
    [21] Sharma R, Valls PO, Inglese M, et al. [(18)F]Fluciclatide PET as a biomarker of response to combination therapy of pazopanib and paclitaxel in platinum-resistant/refractory ovarian cancer[J]. Eur J Nucl Med Mol Imaging, 2020, 47: 1239-1251. doi:  10.1007/s00259-019-04532-z
    [22] Zheng Y, Wang H, Tan H, et al. Evaluation of lung cancer and neuroendocrine neoplasm in a single scan by targeting both somatostatin receptor and integrin αVβ3[J]. Clin Nucl Med, 2019, 44: 687-694. doi:  10.1097/RLU.0000000000002680
    [23] Zhang J, Mao F, Niu G, et al. (68)Ga-BBN-RGD PET/CT for GRPR and integrin alphavbeta3 imaging in patients with breast cancer[J]. Theranostics, 2018, 8: 1121-1130. doi:  10.7150/thno.22601
    [24] Liolios C, Sachpekidis C, Kolocouris A, et al. PET diagnostic molecules utilizing multimeric cyclic RGD peptide analogs for imaging integrin alpha(v)beta(3) receptors[J]. Molecules, 2021, 26: 1792. doi:  10.3390/molecules26061792
    [25] Wu Z, Li ZB, Cai W, et al. 18F-labeled mini-PEG spacered RGD dimer (18F-FPRGD2): synthesis and microPET imaging of alphavbeta3 integrin expression[J]. Eur J Nucl Med Mol Imaging, 2007, 34: 1823-1831. doi:  10.1007/s00259-007-0427-0
    [26] Chen H, Jacobson O, Niu G, et al. Novel "add-On" molecule based on evans blue confers superior pharmacokinetics and transforms drugs to theranostics agents[J]. J Nucl Med, 2017, 58: 590-597. doi:  10.2967/jnumed.116.182097
    [27] Li D, Zhao X, Zhang L, et al. (68)Ga-PRGD2 PET/CT in the evaluation of glioma: a prospective study[J]. Mol Pharm, 2014, 11: 3923-3929. doi:  10.1021/mp5003224
    [28] Kang F, Wang Z, Li G, et al. Inter-heterogeneity and intra-heterogeneity of alpha(v)beta(3) in non-small cell lung cancer and small cell lung cancer patients as revealed by (68)Ga-RGD(2) PET imaging[J]. Eur J Nucl Med Mol Imaging, 2017, 44: 1520-1528. doi:  10.1007/s00259-017-3696-2
    [29] Tonnelet D, Bohn MDP, Becker S, et al. Angiogenesis imaging study using interim[(18)F]RGD-K5 PET/CT in patients with lymphoma undergoing chemotherapy: preliminary evidence[J]. EJNMMI Res, 2021, 11: 37. doi:  10.1186/s13550-021-00776-9
    [30] Jin X, Liang N, Wang M, et al. Integrin imaging with 99mTc-3PRGD2 SPECT/CT shows high specificity in the diagnosis of lymph node metastasis from non-small cell lung cancer[J]. Radiology, 2016, 281: 958-966. doi:  10.1148/radiol.2016150813
    [31] Miao W, Zheng S, Dai H, et al. Comparison of 99mTc-3PRGD2 integrin receptor imaging with 99mTc-MDP bone scan in diagnosis of bone metastasis in patients with lung cancer: A multicenter study[J]. PLoS One, 2014, 9: e111221. doi:  10.1371/journal.pone.0111221
    [32] Li L, Ma L, Shang D, et al. Pretreatment PET/CT imaging of angiogenesis based on (18)F-RGD tracer uptake may predict antiangiogenic response[J]. Eur J Nucl Med Mol Imaging, 2019, 46: 940-947. doi:  10.1007/s00259-018-4143-8
    [33] Sun Y, Zeng Y, Zhu Y, et al. Application of (68)Ga-PRGD2 PET/CT for αVβ3-integrin imaging of myocardial infarction and stroke[J]. Theranostics, 2014, 4: 778-786. doi:  10.7150/thno.8809
    [34] Luo Y, Sun Y, Zhu Z, et al. Is the change of integrin α(v)β(3) expression in the infarcted myocardium related to the clinical outcome?[J]. Clin Nucl Med, 2014, 39: 655-657. doi:  10.1097/RLU.0000000000000426
    [35] Lobeek D, Bouwman FCM, Aarntzen EHJG, et al. A clinical feasibility study to image angiogenesis in patients with arteriovenous malformations using (68)Ga-RGD PET/CT[J]. J Nucl Med, 2020, 61: 270-275. doi:  10.2967/jnumed.119.231167
    [36] Zhu Z, Yin Y, Zheng K, et al. Evaluation of synovial angiogenesis in patients with rheumatoid arthritis using 68Ga-PRGD2 PET/CT: a prospective proof-of-concept cohort study[J]. Ann Rheum Dis, 2014, 73: 1269-1272. doi:  10.1136/annrheumdis-2013-204820
    [37] Lukey PT, Coello C, Gunn R, et al. Clinical quantification of the integrin alphavbeta6 by[(18)F]FB-A20FMDV2 positron emission tomography in healthy and fibrotic human lung (PETAL Study)[J]. Eur J Nucl Med Mol Imaging, 2020, 47: 967-979. doi:  10.1007/s00259-019-04586-z
  • 加载中
图(1) / 表(1)
计量
  • 文章访问数:  995
  • HTML全文浏览量:  93
  • PDF下载量:  389
  • 被引次数: 0
出版历程
  • 收稿日期:  2022-02-27
  • 录用日期:  2022-03-15
  • 刊出日期:  2022-03-30

目录

    /

    返回文章
    返回

    【温馨提醒】近日,《协和医学杂志》编辑部接到作者反映,有多名不法人员冒充期刊编辑发送见刊通知,鼓动作者添加微信,从而骗取版面费的行为。特提醒您,本刊与作者联系的方式均为邮件通知或电话,稿件进度通知邮箱为:mjpumch@126.com,编辑部电话为:010-69154261,请提高警惕,谨防上当受骗!如有任何疑问,请致电编辑部核实。谢谢!